Dominic Rodrigues, Vice Chair of the Board of Directors of Provectus Biopharmaceuticals Inc., called our attention to this news release from the Knoxville-based company announcing dedicated funding that was included in the recently passed State of Tennessee budget for FY22.
According to the announcement, the budget includes “$2.5 million to develop animal health drug products through partnerships with state universities that have agriculture and veterinary medicine programs and the Knoxville-headquartered biotechnology company. This study will pursue oncology, hematology, and dermatology treatments for companion and production animals, furthering research in these areas and eventual drug development.”
The news release adds that the foundation of this study is Provectus Biopharmaceuticals’ halogenated xanthene medical science platform that already includes:
- Safety and efficacy data from companion animal study of solid tumor cancers, such as fibrous histiocytoma, mast cell, melanoma, squamous cell carcinoma, and transitional cell carcinoma; intratumoral, intravesical, intrahepatic, and intraprostatic drug administration;
- Human clinical study of solid tumor cancers; cutaneous and percutaneous intratumoral administration;
- Preclinical study of human solid tumor cancers; oral administration;
- Murine model study of human pediatric solid tumor cancers; intratumoral administration;
- Murine model study of human pediatric leukemias; oral administration; and
- Human clinical study of inflammatory dermatoses; topical administration (as well as preclinical study of systemic administration).